This article was originally published in The Gray Sheet
Firms ink semi-exclusive, worldwide license for patents relating to the development of assays for detection of HIV in nucleic acid sequences in clinical diagnostics, excluding blood screening. Organon is the third licensee of the patents, including Bayer AG and Roche. Chiron will receive royalty payments based on a percentage of net sales of current and future Organon Teknika offerings, subject to minimum royalties as a fixed amount per test sold
You may also be interested in...
BioMerieux-Pierre Fabre's Feb. 15 offer to buy Organon Teknika's diagnostic business would increase the French company's worldwide diagnostic revenues almost 44% to roughly $0.9 bil. annually.
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.